As we move into the fall, I’ve been thinking a lot about what it really takes to turn the promise of drug repurposing into impact for patients. Identifying a promising new use for an existing medicine is an incredibly important first step, but it’s only the beginning. At Every Cure, our goal is to see […]

Last month marked four years since we started Every Cure in August 2022, and we are so thankful for all of the impact that we’ve been able to make together. When we started Every Cure, we had an ambitious idea: build a nonprofit that could systematically identify new uses for existing medicines and help advance […]

One of the most rewarding parts of our work at Every Cure is seeing years of scientific collaboration translate into meaningful progress for patients. This month, we’re excited to share one of those moments. The National Comprehensive Cancer Network (NCCN) recently updated its treatment guidelines for a debilitating rare disease called Rosai-Dorfman disease (RDD), elevating […]

Lenalidomide/dexamethasone (len/dex) is now recommended as a preferred treatment option for patients with Rosai-Dorfman Disease regardless of mutation status, potentially expanding access to an effective,

We’re excited to share that Every Cure recently launched three new drug repurposing programs to help patients with devastating diseases that have few treatment options. One of those programs focuses on a rare mitochondrial disease primarily affecting children and young adults and has no FDA-approved therapies. It’s one of many diseases where we believe drug […]

Shared commitment to ensuring patients receive the medicines they need when and where they are needed

Every Cure submitted a formal response to the FDA’s Request for Information (RFI) on Drug Repurposing for Unmet Medical Needs (Docket No. FDA-2026-N-4492).

Thank you for your continued support of our mission. In addition to sharing important updates this month, we’re excited to share that we now have a place where you can indicate specific diseases that you’re interested in receiving targeted updates about. You can sign up here, and we’ll be in touch if/when we have updates […]

We’re so pleased to highlight two important publications that build upon and reinforce our mission. In one, we worked with partners to evaluate a promising treatment for a rare disorder called Rosai-Dorfman-Destombes disease, which is one of our 10 active drug repurposing programs. In the other, we introduced a new way to measure which diseases […]

Botulinum toxin A (BoNT/A) was surfaced in this screen as a high-ranking treatment for depression. As Many as 12 clinical studies were identified, with 7 randomized, placebo-controlled trials.

In this newsletter, we’ll highlight the progress we’re making — for patients like Jameson, with partners like ARPA-H, and with supporters like Giorgos Tsetis — and show why this work matters. Thank you for being part of this journey with us.

Rosai-Dorfman-Destombes (RDD) disease is a rare histiocytic neoplasm that commonly presents with skin and subcutaneous masses, lymphadenopathy, and bone lesions. Management is guided by disease extent, symptom burden, presence of targetable mutations, and treatment response

Every Cure is deeply grateful to Giorgos Tsetis for his partnership and generous donation to our mission.

Despite the ultimate goal of medical researchers and funders being to maximize patient benefit, there is no systematic process for quantifying unmet medical need across diseases. While a relative unmet medical need scoring system would be valuable for prioritization of medical research, systematically performing this effort across all 22,701 human diseases is technically challenging, time-consuming, […]

New phase of ARPA-H funding will support preclinical and clinical validation of AI-identified repurposing opportunities, building on earlier work that has already yielded 10 active programs. 

A decades-old drug, long used to treat conditions including a chronic parasitic disease, may soon offer new hope..

We are pleased to announce a new partnership with Every Cure. Every Cure is a U.S.-based nonprofit on a mission to save and improve lives by repurposing drugs

Dr. Fajgenbaum is being honored for his groundbreaking work advancing drug repurposing

Millions of patients worldwide live with conditions that have no approved treatments or face barriers to accessing existing therapies. Every Cure, a nonprofit on a mission to save and improve lives by repurposing drugs, categorizes drug repurposing opportunities into four archetypes based on their stage of evidence and adoption…

Pioneering a new field of computational pharmacophenomics to unlock the life-saving potential of existing medicines

When David Fajgenbaum was a twenty-five-year-old medical student, at the University of Pennsylvania, he started to feel so tired that he could barely stand.

Every Cure, a nonprofit working to reveal the untapped potential of existing medications, has emerged as the overall winner of Newsweek’s inaugural AI Impact Awards.

We’re proud to share that Every Cure Co-Founder and President, Dr. David Fajgenbaum, has been named to the 2025 TIME100 Health list, a prestigious recognition honoring the 100 most influential individuals in health today.

A little over a year ago, Joseph Coates was told there was only one thing left to decide. 

Click the video above to watch a story that ran on CBS Evening News about leucovorin for ASD.

Every year, millions of patients suffer from diseases that lack effective treatments…

Set to enter hospice care, a patient with idiopathic multicentric Castleman’s disease is now in remission after treatment with a medication predicated as the top treatment by an AI-guided analysis

In this blog, we highlight the potential role that calcium folinate may play in improving verbal communication in some individuals with speech challenges and certain antibodies that cause a vitamin deficiency in the brain.

Every Cure will leverage Google Cloud’s infrastructure and AI technologies, including Gemini 2.0, to accelerate discoveries and improve patient outcomes

This support will enable Every Cure to evaluate the most promising treatments identified by its ARPA-H-funded AI platform in laboratory and clinical studies, with the goal of democratizing access to safe and effective therapies for patients worldwide.

An organization scouring thousands of existing drugs to see if any can cure hard-to-treat diseases has a powerful new ally: former FDA official Janet Woodcock.

Grant Mitchell discusses Every Cure’s mission, challenges in health tech entrepreneurship, impact assessment, future innovations, and advice for aspiring entrepreneurs.

Rare diseases often require innovative treatments, but not always brand-new ones. This research nonprofit deploys AI as a matchmaker between doctors and existing medications.

We are excited to bring you our newest patient documentary about Kaila, a rare disease patient whose life was saved thanks to a repurposed drug that had never been tried before.

The alliance will focus specifically on enhancing clinical trials and their outcomes to boost trial success rates and the efficient use of capital by drug developers.

New Technologies Will Enable Every Cure to Bolster its Computational Drug Development, Drug Repurposing, and Clinical Trial Simulation Efforts – Uncovering More Approved Drugs to Treat Patients

ABC News’ Rebecca Jarvis looks at artificial intelligence’s role in the medical field and how it’s allowing doctors to expand their research and make decisions for patients.

We talk with a doctor who discovered a cure for rare diseases with the help of artificial intelligence.

Every Cure was excited to announce our 3 year, 48.3M contract with ARPA-H at the White House! The ARPA-H contract is aimed to develop our AI-Driven platform to revolutionize future of drug development and repurposing.

A nonprofit that seeks to repurpose approved drugs for new indications will receive more than $48 million from the U.S. Advanced Research Projects Agency for Health to supercharge its work, the agency said on 28 February.

Over the past few years, Every Cure has developed a blueprint for an AI-powered platform that can do what humans can’t — match thousands of diseases with thousands of drugs.

Every Cure, cofounded by Penn’s David Fajgenbaum, received a three-year $48 million federal contract to develop an AI tool for rare diseases.

Agency backs non-profit’s agnostic approach to drug repurposing with $48.3M

ABC News chief medical correspondent Dr. Jen Ashton discusses Every Cure’s AI platform that aims to match FDA-approved drugs with diseases currently lacking approved treatments.

On this Rare Disease Day, we are highlighting Madison, a patient diagnosed with a rare form of leukodystrophy (LBSL) who is fighting for her ability to walk.

The White House is hoping to use AI to match already approved drugs with untreated diseases. The federal government is giving nonprofit Every Cure nearly $50 million to develop the technology.

New database aims to match rare-disease patients with drugs on pharmacy shelves

ARPA-H contract will supercharge Every Cure’s work to identify existing medicines that can be repurposed to treat currently untreated diseases. Initial progress utilizing a pilot version of the AI platform and stakeholder engagement has led to the identification of potential treatments for sickle cell disease, ALS, and autism spectrum disorder.

The three-year, $48.3 million ARPA-H contract will supercharge Every Cure’s work to identify existing medicines that can be repurposed to treat currently untreated diseases.

Winning startups join more than 20 companies at New York City’s cutting-edge healthcare innovation campus

Dr. David Fajgenbaum saved his own life by tracking down a generic drug that cured his rare and deadly disease. Now with nonprofit Every Cure, he’s seeking cures for the estimated 9,000+ untreatable rare diseases — and fast.

David Fajgenbaum discovered a repurposed drug to save his own life and is now on a mission with Every Cure Co-Founders Grant Mitchell and Tracey Sikora to repurpose drugs for millions more. 

Every Cure is a non-profit, founded by Dr. David Fajgenbaum following his brush with a near-fatal rare disease that doctors struggled to diagnose, that finds new uses for existing drugs. Atropos Health, meanwhile, was founded by Dr. Brigham Hyde to eliminate disparity in underserved populations via drug repurposing following his mother’s battle with a rare blood cancer.

New Partnership Enables Real World Data Confirmation of Drug Repurposing Opportunities and Trial Emulation Capabilities to Speed Clinical Development

This Challenge is a bold initiative to incubate innovations by healthcare start-ups and entrepreneurs across disciplines and sectors to responsibly and equitably use artificial intelligence (AI).

AI has also enabled the discovery of a new application for an existing drug in treating a rare disease, iMCD. This development represents a significant breakthrough, showcasing the power of AI in identifying and repurposing existing drugs for new therapeutic uses.

The Fierce 50 special report shines a spotlight on those who are making a significant impact and driving progress in the pharmaceutical, healthcare and biotech industries

Since the advent of modern medicine, the scientific community has developed more than 3,000 drugs for thousands of diseases. Despite significant progress, there are more than 6,500 rare diseases without a single approved treatment.

David Fajgenbaum discovered a repurposed drug to save his own life and is now on a mission with Every Cure Co-Founders Grant Mitchell and Tracey Sikora to repurpose drugs for millions more.

He’s alive thanks to a repurposed drug. Now his dream is to find cures for millions of people from among drugs we already have.

While rare diseases are defined as conditions affecting fewer than 200,000 individuals, the shortage of rare disease treatments in the United States is a significant and pressing issue that affects countless individuals and their families who are grappling with often life-threatening medical conditions

On September 23rd, Every Cure Co-Founder David Fajgenbaum addressed Chan Zuckerberg Initiative’s Rare as One Network at the Science in Society Annual Meeting about the learnings and opportunities from his work to found and lead Every Cure, a nonprofit drug development organization focused on advancing repurposed treatments. 

Partnerships with the Chan Zuckerberg Initiative, Flagship Pioneering, Lyda Hill Philanthropies, and Elevate Prize Foundation Will Accelerate the Discovery of Cures Hidden on Pharmacy Shelves

Board of Directors will lead the nonprofit organization on its mission of unlocking hidden cures.

Research driven by patients with rare diseases is producing faster discoveries and treatments—and challenging long-held assumptions about knowledge production.

Imagine feeling like you’ve contracted the flu, only to fall into a coma three days later. This was Gary’s reality, an experience he describes as having “fatigue on a different level.” This wasn’t any ordinary illness; this was Castleman Disease. Through the heartbreaking and hope-filled chapters of Gary’s journey, the undeniable power of drug repurposing […]

Have you read the story of David Fajgenbaum, a physician who was diagnosed with the rare disease called Castleman disease?

An Angiosarcoma patient facing a grave prognosis found a lifeline in a repurposed PD-1 inhibitor, a treatment hidden in the medical literature for three years. Every Cure and its partners are building on this breakthrough, deploying innovative AI algorithms that evaluate the potential of every drug for every disease. The efforts have already begun to […]

In a recent address to the Rare Disease Congressional Caucus, David Fajgenbaum, the co-founder of Every Cure, unveiled the organization’s mission to repurposing FDA-approved drugs for diseases that currently have no cure. By leveraging the vast pharmaceutical world’s existing knowledge, Every Cure aims to revolutionize treatment paradigms for thousands who have been told, “We’ve tried […]

A patient’s life was saved after researchers at the University of Pennsylvania, Castleman Disease Collaborative Network, Medidata, and Every Cure, used artificial intelligence to use an existing drug to treat idiopathic multicentric Castleman disease (iMCD).

Of course, AI was on everyone’s minds at the conference. However, it was the proof points and examples shared by leaders from multiple organizations that signaled the dramatic surge in impact.

The adoption of AI is accelerating across the entire CRO space as we start to explore the benefits of the tech. Whether being utilised for CRO expansion, streamlined clinical trials, better data analysis or another application we’ve yet to discover.

Aspen, Colorado – David Fajgenbaum, co-founder of Every Cure and physician-scientist at the University of Pennsylvania, unveiled his ‘Big Idea’ to repurpose existing drugs for the treatment of various diseases at the Aspen Idea Health Conference. Fajgenbaum’s personal battle with Castleman Disease during his time as a medical student inspired his mission to explore the […]

Every Cure has raised significant awareness over the last year and engaged with leaders across healthcare and government. In fact, Every Cure Co-Founders Grant Mitchell and David Fajgenbaum (pictured above) met with President Biden’s Chief of Staff, Jeff Zients, in the White House.

We are very excited to have Dr. David Fajgenbaum as our student-selected keynote speaker on this momentous occasion of our 50th commencement ceremony. His impressive and lofty goals and accomplishments will serve as a lasting inspiration to our students and anyone in attendance,” stated Dr. David Guzick, Chancellor of LSU Health Shreveport.

Miami, Florida – David Fajgenbaum, co-founder of Every Cure, delivered a presentation at the Elevate Prize’s Make Good Famous Summit, sharing his journey with illness and his mission to repurpose existing drugs for the treatment of various diseases.  In a moving speech at the Make Good Famous Summit in Miami, David Fajgenbaum, co-founder of Every […]

In September 2022, Fajgenbaum joined forces with longtime friend and fellow doctor Grant Mitchell, MD, and a group of experts at the University of North Carolina and beyond to leverage the power of machine learning to sift through the ocean of existing medical research to connect rare diseases to existing drugs. Their organization is called […]

Worldwide Clinical Trials (Worldwide), the industry’s leading global, full-service contract research organization (CRO), has partnered with Every Cure, a nonprofit organization that unlocks new, often undiscovered uses for existing approved drugs by leveraging data, artificial intelligence (AI), and efficient clinical trials.

David Fajgenbaum is an immunologist and co-founder of Every Cure, a nonprofit organization whose mission is to unlock the full potential of approved medicines to treat every disease possible. The organization, which he launched at the Clinton Global Initiative in 2022, employs AI to search through existing data to identify potential additional indications for approved […]

San Francisco, California – David Fajgenbaum, co-founder of Every Cure and physician-scientist at the University of Pennsylvania, announces First Life Saved with AI-Discovered Repurposed Medicine for Castleman Disease with Significant Potential Applications to Treat Other Illnesses

Fajgenbaum was having his last rites read to him, and his family braced for his death from Castleman disease, a rare inflammatory illness that impacts the lymph nodes and can severely damage other organs.

A 50-year-old patient battling life-threatening Castleman disease was provided adalimumab as a treatment of last resort following its identification by AI-guided discovery. Every Cure and its partners are expanding upon this discovery to harness a novel AI algorithm that calculates the potential use of every drug to treat every disease. Initial promising candidates for further […]

About a decade ago, David Fajgenbaum thought his life was over. He was a young, bright physician hoping to work in oncology in remembrance of his mother, who died of brain cancer a few years earlier. Fajgenbaum was having his last rites read to him, and his family braced for his death from Castleman disease, […]

David Fajgenbaum has become a “man on fire,” determined to repurpose as many generic drugs as possible for diseases without approved treatments. Fajgenbaum, whose efforts have been recognized by former President Bill Clinton, spoke with In Vivo about his own patient journey with a disease with no approved treatment and about the Every Cure Foundation, a non-profit […]

Two companies team up to combat rare diseases through drug repurposing, which was heavily informed by one doctor’s experience through unconventionally treating his Castleman disease and (ultimately) saving his own life. Two companies join forces to unlock the hidden potential in existing drugs to save lives suffering from rare diseases. In 2010, Dr. David Fajgenbaum, […]

David Fajgenbaum, MD, was a college football player at Georgetown University in 2004 when his mother passed away from cancer. The loss inspired the athlete to become a doctor himself: “I wanted to treat patients in memory of my mom,” he says. But three years into medical school, the then-25-year-old’s health took a turn for […]

As many as 7,000 rare diseases affect 300 million people globally. The vast majority are not well understood, and less than 5 percent have approved treatments. Yet, patients are meeting these challenges head-on. Dr. Fajgenbaum was diagnosed with Castleman disease, a rare disorder that involves an overgrowth of cells in your body’s lymph nodes. The most […]

Dr. David Fajgenbaum is not afraid to think outside the box and that is what saved his life. While in medical school, the former college athlete suddenly became critically ill. Doctors told him he was suffering from a rare disorder called Castleman disease; his immune system was attacking his vital organs, potentially leading to life-threatening […]

It was the night before April Fools’ Day, 2021, when Dr. David Fajgenbaum received the text: President Clinton read your book and would like to talk. Despite the outpouring of praise for his bestselling memoir, Chasing My Cure – an astounding chronicle of Fajgenbaum’s five near-death experiences from Castleman disease and his successful search to […]

The Philadelphia physician has the distinction of researching – and solving – his own rare disease. Learn more about this prolific advocate for rare disease patients. Maybe it’s the brush with death that David Fajgenbaum had at a young age that gave him an extra charge of energy, a powerful desire to get things done.

For biotechs, the JP Morgan Healthcare Conference is about dealmaking in many forms—securing financing, establishing development partnerships, courting mergers and acquisitions—by wooing would-be partners and investors with a value proposition. Everyone’s in schmooze-and-pitch mode, and everyone’s seeking to capitalize on the momentum the show generates in the news cycle.

Medable has announced a collaboration with non-profit Every Cure for conducting global, remote clinical trials for drug repurposing candidates. Every Cure was officially launched, in collaboration with the Clinton Global Initiative, in September to scale up a new ‘drug repurposing’ research approach for identifying rare disease treatments.

Medable Inc., the industry-leading technology platform for patient-centered clinical trials, today announced a partnership with non-profit Every Cure, which officially launched in September in partnership with the Clinton Global Initiative to scale up an innovative “drug repurposing” research approach to identify treatments for rare diseases.

President Biden found a copy of the book “Chasing My Cure” on his desk, a gift from none other than former President Clinton.

This week, an exciting interview from our archive airs on Oct. 8, 2022. A healthy young medical student, David Fajgenbaum, had been a student athlete in college and maintained his extraordinary level of fitness through much of medical school. Because of his enthusiasm and athleticism, his friends called him The Beast. When he suddenly found […]

A new nonprofit backed by the Clinton Global Initiative aims to identify generic drugs that could help people with rare diseases. Every Cure is based on the concept that every drug on the market has multiple effects on the body, not just the one or two that first earned its approval.

A new nonprofit backed by the Clinton Global Initiative aims to identify generic drugs that could help people with rare diseases. Every Cure is based on the concept that every drug on the market has multiple effects on the body, not just the one or two that first earned its approval.

Every drug on the market has multiple effects on the body, not just the one or two that won it approval. A new nonprofit aims to exploit those other effects to help patients with rare diseases.